Akari Therapeutics FY2024 net loss $21.6M; cash runway into Sep 2025; new CEO named

Akari Therapeutics Plc

2025-Q1 EPS reported $0.00

FY2024 net loss from operations $21.6M vs $16.8M in 2023; R&D $7.0M, G&A $9.7M.
Cash $2.6M at Dec 31, 2024; plus $6.6M private placement in March 2025 funds operations into Sep 2025.
Lead ADC AKTX-101 (TROP2 PH1) for solid tumors; seeking licensing/strategic partner.
Abizer Gaslightwala named President and CEO effective April 21, 2025.
Merger with Peak Bio completed Nov 2024; pipeline focused on next-gen bifunctional ADCs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.